| Serial Number | 98195969 |
| Word Mark | REMIX THERAPEUTICS |
| Filing Date | Monday, September 25, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, January 7, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 26, 2024 |
| Goods and Services | Pharmaceutical preparations for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; pharmacuetical preparations for the use in gene therapy for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; preparations for detecting mutation in RNA genes for medical purposes |
| NOT AVAILABLE | THERAPEUTICS |
| Goods and Services | development of gene-based medicines; gene therapy and modulation research; laboratory research in the fields of degrading and enhancing RNA including exon skipping and rescue genetic lesions; Medical and scientific research in the fields of genetics, genomics, gene modulation and genetic engineering; DNA and RNA analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics and gene modulation |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, June 26, 2024 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, June 26, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Remix Therapeutics Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02139 |
| Party Name | Remix Therapeutics Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02139 |
| Event Date | Event Description |
| Tuesday, October 10, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 16, 2024 | ASSIGNED TO EXAMINER |
| Friday, May 17, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, May 17, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, May 17, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, June 26, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 26, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, June 26, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, June 27, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, June 27, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, June 27, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, September 23, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, September 23, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, September 23, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, October 3, 2024 | FINAL REFUSAL E-MAILED |
| Thursday, October 3, 2024 | FINAL REFUSAL WRITTEN |
| Thursday, October 3, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, October 21, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Monday, October 21, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, October 21, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, October 21, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Monday, October 21, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, November 20, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 26, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, November 26, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 7, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |